Press Releases

 
Press Releases
  Date Title and Summary View
Nov 21, 2017
The trial is being conducted with a biomarker assay to identify FGFR2 fusions BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced dosing of the initial patients in a registrational trial with its FGFR inhibitor, derazantinib (ARQ 087) in FGFR2 fusion dri...
Nov 9, 2017
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the third quarter of 2017. For the quarter ended September 30, 2017, the Company reported a net loss of...
Nov 8, 2017
The Pontifax Group led this financing with additional participation from an Israeli-based healthcare equity fund Ran Nussbaum, Managing Partner and co-founder of The Pontifax Group, joins ArQule Board BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) t...
Nov 1, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation to miransertib (ARQ 092) for the treatment of Proteus syndrome. Under the FDA's rare pediatric disease priority review voucher program, t...
Oct 26, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the third quarter 2017 before the market opens on Thursday, November 9, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results ...
Oct 16, 2017
Company also raises approximately $4M through unrelated business development activities and other sources during September-October BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (NASDAQ: ARQL) today announced the closing of a private placement with certain institutional investors, with le...
Sep 19, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that Paolo Pucci, Chief Executive Officer, and Dr. Brian Schwartz, M.D., Head of Research and Development and Chief Medical Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on September 26th, 2017,...
Aug 4, 2017
Conference call scheduled today at 9:00 a.m. ET BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced its financial results for the second quarter of 2017. For the quarter ended June 30, 2017, the Company reported a net loss of $7,...
Jul 21, 2017
BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced it will report financial results for the second quarter 2017 before the market opens on Friday, August 4, 2017. The Company will hold a conference call and webcast on the same day at 9:00 a.m. ET to discuss these results and...
Jul 11, 2017
Trial is enrolling patients refractory to standard of care, including ibrutinib BURLINGTON, Mass.--(BUSINESS WIRE)-- ArQule, Inc. (Nasdaq: ARQL) today announced that the first patient has been dosed in a phase 1a/b trial with its BTK inhibitor, ARQ 531, in patients with B-cell malig...
Page:
1
... NextLast
= add release to Briefcase

Questions or Concerns?

Please feel free to contact by one of the methods below

Online Form   Call (781) 994-0300